These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22283844)

  • 1. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.
    Horsley L; Marti K; Jayson GC
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):283-93. PubMed ID: 22283844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
    Launay-Vacher V; Deray G
    Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
    van Heeckeren WJ; Ortiz J; Cooney MM; Remick SC
    J Clin Oncol; 2007 Jul; 25(21):2993-5. PubMed ID: 17634476
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-angiogenic drug discovery: lessons from the past and thoughts for the future.
    Wu JM; Staton CA
    Expert Opin Drug Discov; 2012 Aug; 7(8):723-43. PubMed ID: 22716277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anticancer drugs under pressure].
    Ben Aïssa A; George AC; El M'Rabet FZ; Mach N; Dietrich PY; Pechère-Bertschi A
    Rev Med Suisse; 2011 Sep; 7(308):1761-6. PubMed ID: 21954818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting angiogenesis in head and neck cancer.
    Seiwert TY; Cohen EE
    Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity].
    Izzedine H
    Bull Cancer; 2007 Nov; 94(11):981-6. PubMed ID: 18055316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
    Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
    Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteinuria and VEGF-targeted therapies: 
an underestimated toxicity?
    Izzedine H; Soria JC; Escudier B
    J Nephrol; 2013; 26(5):807-10. PubMed ID: 24052461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uncontrolled Hypertension and Oncology: Clinical Tips.
    Kalaitzidis RG; Elisaf MS
    Curr Vasc Pharmacol; 2017; 16(1):23-29. PubMed ID: 28413967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
    Izzedine H; Massard C; Spano JP; Goldwasser F; Khayat D; Soria JC
    Eur J Cancer; 2010 Jan; 46(2):439-48. PubMed ID: 20006922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy.
    Eremina V; Quaggin SE
    Semin Nephrol; 2010 Nov; 30(6):582-90. PubMed ID: 21146123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing patients treated with bevacizumab combination therapy.
    Gordon MS; Cunningham D
    Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intricacies of bevacizumab-induced toxicities and their management.
    Gressett SM; Shah SR
    Ann Pharmacother; 2009 Mar; 43(3):490-501. PubMed ID: 19261963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges for patient selection with VEGF inhibitors.
    Longo R; Gasparini G
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):151-70. PubMed ID: 17370072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors.
    Ishak RS; Aad SA; Kyei A; Farhat FS
    Crit Rev Oncol Hematol; 2014 May; 90(2):152-64. PubMed ID: 24355408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel targets for VEGF-independent anti-angiogenic drugs.
    Petrillo M; Scambia G; Ferrandina G
    Expert Opin Investig Drugs; 2012 Apr; 21(4):451-72. PubMed ID: 22339615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic-induced hypertension: the molecular basis of signaling network.
    Nagai A; Sado T; Naruse K; Noguchi T; Haruta S; Yoshida S; Tanase Y; Tsunemi T; Kobayashi H
    Gynecol Obstet Invest; 2012; 73(2):89-98. PubMed ID: 22222493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab and ovarian cancer.
    Sato S; Itamochi H
    Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.